» Articles » PMID: 17235328

Dimethylfumarate Induces Immunosuppression Via Glutathione Depletion and Subsequent Induction of Heme Oxygenase 1

Overview
Publisher Elsevier
Specialty Dermatology
Date 2007 Jan 20
PMID 17235328
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

A mixture of different fumaric acid esters (FAE) is established for systemic therapy of psoriasis, a frequent inflammatory skin disease. The main active compound of FAE, however, has not been identified so far, and the mechanisms of activity are only partially understood. We analyzed the impact of FAE on in vitro immune function and aimed to gain knowledge about the mode of action. Dimethylfumarate (DMF) and diethylfumarate (DEF), but not fumaric acid, methylhydrogenfumarate and ethylhydrogenfumarate, exhibited potent depression of inflammatory cytokine secretion (e.g., tumor necrosis factoralpha, IL-12, and IFNgamma) in activated human peripheral blood mononuclear cells. Moreover, solely DMF and DEF inhibited alloreactive T-cell proliferation in mixed leukocyte reaction. Interestingly, these immunosuppressive effects were accompanied by the strong induction of the anti-inflammatory stress protein heme oxygenase 1 (HO-1). Supplementation with exogenous glutathione (GSH), which is known to bind DMF, prevented both HO-1 induction as well as the anti-inflammatory effects of DMF. Moreover, inhibition of HO-1 activity restored the diminished IL-12 and IFNgamma production after FAE treatment. These results suggest that DMF acts as active compound within the FAE mixture and at least partially mediates its immunomodulatory activity by the induction of the anti-inflammatory stress protein HO-1 ascribed to the functional depletion of reduced GSH.

Citing Articles

Electrostimulation: A Promising New Treatment for Psoriasis.

Zuo Z, Wang Y, Fang Y, Wang Z, Yang Z, Jia B Int J Mol Sci. 2024; 25(23).

PMID: 39684717 PMC: 11641613. DOI: 10.3390/ijms252313005.


Immune cell targeted fumaric esters support a role of GPR109A as a primary target of monomethyl fumarate in vivo.

Strass S, Geiger J, Cloos N, Spath N, Geiger S, Schwamborn A Inflammopharmacology. 2023; 31(3):1223-1239.

PMID: 37004600 DOI: 10.1007/s10787-023-01186-0.


Polymeric Nanoparticles as Tunable Nanocarriers for Targeted Delivery of Drugs to Skin Tissues for Treatment of Topical Skin Diseases.

Madawi E, Al Jayoush A, Rawas-Qalaji M, Thu H, Khan S, Sohail M Pharmaceutics. 2023; 15(2).

PMID: 36839979 PMC: 9964857. DOI: 10.3390/pharmaceutics15020657.


Epigenetics and Metabolism Reprogramming Interplay into Glioblastoma: Novel Insights on Immunosuppressive Mechanisms.

Torrisi F, DAprile S, Denaro S, Pavone A, Alberghina C, Zappala A Antioxidants (Basel). 2023; 12(2).

PMID: 36829778 PMC: 9952003. DOI: 10.3390/antiox12020220.


Ferroptosis-modulating small molecules for targeting drug-resistant cancer: Challenges and opportunities in manipulating redox signaling.

Koeberle S, Kipp A, Stuppner H, Koeberle A Med Res Rev. 2023; 43(3):614-682.

PMID: 36658724 PMC: 10947485. DOI: 10.1002/med.21933.